6月9日，福瑞股份今日收盘34.42元，上涨1.12%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到92.42倍，总市值91.68亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.64倍，行业中值37.05倍，福瑞股份排 名第105位。 来源：金融界 资金流向方面，6月9日，福瑞股份主力资金净流入1610.78万元，近5日总体呈流出状态，5日共流出 8787.63万元。 内蒙古福瑞医疗科技股份有限公司的主营业务是肝病领域的药品生产与销售、诊断设备研发与销售以及 医疗服务相关业务。公司的主要产品是复方鳖甲软肝片。 最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)105福瑞股份92.4280.935.1491.68亿行业平均 50.6449.074.68109.10亿行业中值37.0537.632.5050.67亿1天益医疗-1817.92-3113.901.9423.17亿2澳华内 镜-726.69364.475.82 ...

内蒙古福瑞医疗科技股份有限公司的主营业务是肝病领域的药品生产与销售、诊断设备研发与销售以及 医疗服务相关业务。公司的主要产品是复方鳖甲软肝片。 6月5日，福瑞股份今日收盘34.44元，下跌1.82%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到92.47倍，总市值91.73亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.97倍，行业中值36.67倍，福瑞股份排 名第106位。 资金流向方面，6月5日，福瑞股份主力资金净流出3761.22万元，近5日总体呈流出状态，5日共流出 10230.71万元。 最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)106福瑞股份92.4780.985.1591.73亿行业平均 50.9748.964.68108.42亿行业中值36.6736.602.4749.87亿1天益医疗-1782.30-3052.891.9022.71亿2澳华内 镜-692.58347.365.5572.99亿 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][8]. Core Views - The company is positioned as a "water seller" in the MASH (Metabolic Associated Steatotic Hepatitis) market, with significant growth potential expected in the coming years [7][8]. - The company has a comprehensive product portfolio that includes pharmaceuticals, diagnostic equipment, and medical services, focusing on liver health management [7][18]. - The demand for liver disease screening is anticipated to surge due to the emergence of new MASH drugs and the establishment of screening protocols in medical institutions [7][8]. Summary by Sections 1. Focus on Liver Disease - The company has over 20 years of experience in the liver disease sector and has actively pursued overseas acquisitions and global expansion [18]. - It offers a complete product/service combination of drugs (notably the patented Fufang Bie Jia Ruan Gan Pian), diagnostic devices (FibroScan series), and medical services [20][21][22]. 2. FibroScan and Market Potential - FibroScan is recognized as a leading diagnostic tool in the liver disease field, with over 5,200 clinical research publications supporting its efficacy [7][21][67]. - The global prevalence of liver diseases, particularly MASH, is significant, with early diagnosis being crucial for reversing liver fibrosis [43][44]. - The report highlights the rapid progress of MASH drug development, with several drugs expected to be approved soon, which will likely increase the demand for liver screening [54][60]. 3. Financial Projections - Revenue projections for the company are set at 16.77 billion yuan, 20.63 billion yuan, and 25.06 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 24.3%, 23.0%, and 21.4% [6][8]. - The net profit attributable to the parent company is expected to reach 2.21 billion yuan, 3.14 billion yuan, and 4.29 billion yuan for the same years, with growth rates of 95.5%, 41.6%, and 36.9% [6][8]. 4. Competitive Landscape and Market Strategy - The company is well-positioned in the academic field of liver disease diagnostics and has established a strong customer base in both domestic and international markets [7][8]. - The introduction of a pay-per-use model for FibroScan devices is expected to enhance market penetration, particularly in primary healthcare settings [36][70]. 5. Valuation - The company's reasonable market capitalization is estimated at 14 billion yuan, indicating a potential upside of approximately 48% relative to its market value as of May 30, 2025 [8].

Group 1 - The core viewpoint of the article highlights that Furuya Co., Ltd. has seen a stock price increase of 5.15% to 33.47 yuan, with a rolling PE ratio of 89.87, marking a new low in 44 days, and a total market capitalization of 8.915 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 49.11, with a median of 35.89, placing Furuya Co., Ltd. at the 106th position in the industry ranking [1] - The company reported a net inflow of 16.2962 million yuan in main funds on May 27, with a total inflow of 38.9964 million yuan over the past five days, indicating a positive trend in fund flow [1] Group 2 - Furuya Co., Ltd. specializes in the production and sales of drugs in the field of liver disease, development and sales of diagnostic equipment, and related medical services, with its main product being the Compound Turtle Shell Soft Liver Tablets [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97%, with a gross profit margin of 76.76% [1]

Group 1 - The company decided to repurchase and cancel 1.3802 million restricted shares from 104 incentive recipients at a price of 18.09 yuan per share due to certain conditions not being met [1][2] - The repurchase is a result of 8 incentive recipients leaving the company and the 2024 net profit not meeting the performance assessment criteria for the first release period [2] - Following the repurchase, the total number of shares will decrease by 1.3802 million [2] Group 2 - The company is required to notify creditors due to the reduction in registered capital resulting from the share repurchase [3] - Creditors have 30 days from receiving the notice, or 45 days from the public announcement if no notice is received, to claim their debts or request guarantees [3] - Required documents for claims include original and copies of contracts proving the debt relationship, along with identification for legal entities and individuals [3]

证券代码：300049 证券简称：福瑞股份 公告编号：2025-024 内蒙古福瑞医疗科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议； 3、为尊重中小投资者利益，提高中小投资者对公司股东会决议的重大事项的参与度， 本次股东会对中小投资者单独计票。 一、会议召开情况 1、股东会届次：2024 年年度股东会 2、股东会的召集人：内蒙古福瑞医疗科技股份有限公司董事会 3、会议召开的合法性、合规性：经公司第八届董事会第十三次会议审议通过，决定 召开 2024 年年度股东会，本次股东会的召开符合有关法律法规、深圳证券交易所业务规 则和公司章程等的规定。 4、会议召开的日期、时间： （1）现场会议时间：2025 年 5 月 21 日（星期三）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 21 日 9:15~9:25、9:30~11:30、13:00~15:00；通过深 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2025-026 内蒙古福瑞医疗科技股份有限公司 关于独立董事及董事会专门委员会成员变更完成的公告 股东会完成独立董事变更后，公司第八届董事会各专门委员会组成情况如下： 三、独立董事辞职情况 郭朋先生因个人原因，申请辞去公司独立董事及提名委员会主任委员、人力资源与 薪酬委员会主任委员、审计委员会委员职务，辞职后不再担任公司任何职务。具体内容 详见公司于 2025 年 4 月 22 日披露于巨潮资讯网（www.cninfo.com.cn）的《关于变更独 1、战略发展委员会：王冠一（主任委员）、邓丽娟、杨勇 2、提名委员会：贺颖奇（主任委员）、郭晋龙、王冠一 3、人力资源与薪酬委员会：贺颖奇（主任委员）、郭晋龙、邓丽娟 4、审计委员会：郭晋龙（主任委员）、贺颖奇、杨勇 立董事及调整董事会专门委员会委员暨聘任证券事务代表的公告》（公告编号：2025-017）。 截至本公告披露日，郭朋先生未持有公司股份，不存在应当履行而未履行的承诺事 项。郭朋先生在担任公司独立董事期间，勤勉尽责、恪尽职守、独立公正，在公司规范 运作和健康发展等方面发挥了积极有效的作用，公司对郭朋 ...

北京金诚同达律师事务所 关于 内蒙古福瑞医疗科技股份有限公司 2024 年年度股东会的 法律意见书 金证法意[2025]字 0521 第 0473 号 中国北京市建国门外大街1号国贸大厦A座十层 100004 电话：010-5706 8585 传真：010-6518 5057 金诚同达律师事务所 法律意见书 北京金诚同达律师事务所 关于内蒙古福瑞医疗科技股份有限公司 2024 年年度股东会的 法律意见书 金证法意[2025]字 0521 第 0473 号 致：内蒙古福瑞医疗科技股份有限公司 北京金诚同达律师事务所（以下简称"本所"）接受内蒙古福瑞医疗科技股 份有限公司（以下简称"公司 "）的聘请，指派本所律师出席公司2024 年年度 股东会（以下简称"本次股东会"）并对会议的相关事项出具法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"） 《律师事务所从事证券法律业务管理办法（2023）》《律师事务所证券法律业务 执业规则（试行）》等有关法律、法规和规范性文件的要求以及《内蒙古福瑞医 疗科技股份有限公司章程 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2025-025 《关于回购注销2024年限制性股票激励计划部分限制性股票的公告》（公告编号： 2025-018）。 内蒙古福瑞医疗科技股份有限公司 关于回购注销部分限制性股票通知债权人的公告 二、需债权人知晓的相关情况 由于公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华人 民共和国公司法》（以下简称"《公司法》"）等相关法律法规的规定，公司特此通 知债权人，公司债权人自接到公司通知起30日内、未接到通知者自本公告披露之 日起45日内，均有权凭有效债权文件及相关凭证要求公司清偿债务或者提供相应 担保。债权人如逾期未向公司申报债权，不会影响其债权的有效性，相关债务（义 务）将由公司根据原债权文件的约定继续履行。债权人未在规定期限内行使上述 权利的，本次回购注销将按法定程序继续实施。公司债权人如要求公司清偿债务 或提供相应担保的，应根据《公司法》等相关法律法规的有关规定向公司提出书 面要求，并随附有关证明文件。 债权申报所需材料：公司债权人可持证明债权债务关系存在的合同、协议及 其他凭证的原件及复印件到公司申报债权。债权人为法人的，需同时携带法人 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Furuya Co., which operates in the medical device industry, specifically focusing on liver disease-related products and services [1][2] - As of May 19, Furuya Co. closed at 30.48 yuan, with a decline of 1.20%, resulting in a rolling price-to-earnings (PE) ratio of 81.84 times, significantly higher than the industry average of 49.26 times and the median of 36.71 times [1][2] - The total market capitalization of Furuya Co. is reported at 8.119 billion yuan, ranking it 102nd in the industry based on PE ratio [1][2] Group 2 - For the first quarter of 2025, Furuya Co. reported a revenue of 330 million yuan, reflecting a year-on-year increase of 2.35%, while the net profit was 28.637 million yuan, showing a decline of 32.97% compared to the previous year [1] - The gross profit margin for Furuya Co. stands at 76.76%, indicating a strong profitability despite the drop in net profit [1] - As of the first quarter of 2025, 18 institutions hold shares in Furuya Co., including 14 funds, 3 other entities, and 1 insurance company, with a total holding of 49.9011 million shares valued at 1.593 billion yuan [1]